SAN DIEGO鈥擣inal analysis of survival rates from patients enrolled in a major phase III clinical trial has shown that 5-year survival for patients with inoperable, locally advanced nonsmall cell lung cancer (NSCLC) who undergo chemotherapy and radiation is likely more than two times higher...
[15] Choi J, Lee JE, Choi CM, et al. A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation...
The two main types of lung cancer aresmall-cell lung cancerand non-small-cell lung cancer.Non-small-cell lung cancer is a catchall term for all lung cancers that are the not small-cell type. They are grouped together because the treatment is often the same for all non-small-cell types....
[3]DyerM, GreenM, Joness, et al. Estimating long-term survival of previously untreated patients with EGFR mutation-positive (EGFRm) advanced non-small cell lung cancer (NSCLC) who received osimertinib in the FLAURA study[J]. J Clin Oncol, 2019, 37(15Suppl): e20560-e20560. DOI: 10.120...
{A recent randomized radiation dose–escalation trial in unresectable stage III non–small-cell lung cancer (NSCLC) (Radiation Therapy Oncology Group [RTOG] 0617) showed a lower survival rate in the high-dose radiation therapy (RT) arm (74 Gy) than in the low-dose arm (60 Gy) with ...
前瞻性临床研究结果显示,2015—2017年中国局部晚期和(或)晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)患者的中位总生存时间(overall survival, OS)为23.2个月。回顾性临床研究显示,2011—2018年在中国医学科学院肿瘤医院诊治的358例广泛期小细胞肺癌(small cell lung cancer, SCLC)患者的中位OS为14个月...
前瞻性临床研究结果显示,2015—2017年中国局部晚期和(或)晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)患者的中位总生存时间(overall survival, OS)为23.2个月。回顾性临床研究显示,2011—2018年在中国医学科学院肿瘤医院诊治的358例广泛期小细胞肺癌(small cell lung cancer, SCLC)患者的中位OS为14个月...
Amanam I, Mambetsariev I, Gupta R, et al. Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival. J Thorac Dis, 2020, 12(9): 5086-5095. doi: 10.21037/jtd.2020.04.18 Adderley H, Blackhall FH, Lindsay CR. KRAS-mutant non-small cell lung cancer: ...
肺癌是国内发病率最高和死亡率最高的癌症之一,其中非小细胞肺癌(non-small cell lung cancer,NSCLC)约占所有肺癌的85%。较传统的化疗方案,靶向治疗和免疫治疗极大地提高了晚期NSCLC患者的生存率,5年总生存(overall survival,OS)率达到了20%~30%[1-4]。在晚期的NSCLC取得成功后,靶向治疗和免疫治疗进一步拓展到早...
肺癌是国内发病率最高和死亡率最高的癌症之一,其中非小细胞肺癌(non-small cell lung cancer,NSCLC)约占所有肺癌的85%。较传统的化疗方案,靶向治疗和免疫治疗极大地提高了晚期NSCLC患者的生存率,5年总生存(overall survival,OS)率达到了20%~30%[1-4]。在晚期的NSCLC取得成功后,靶向治疗和免疫治疗进一步拓展到早...